A randomized, double-blind, placebo-controlled trial to evaluate the hypoglycemic efficacy of the mcIRBP-19-containing <i>Momordica charantia</i> L. fruit extracts in the type 2 diabetic subjects.

Food Nutr Res · 2022 · PMC8788657 · PMID 35140559

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.0570

boldest claim

The sentences

borderline significantP = 0.051so close (0.05 < p ≤ 0.1)

The change from baseline evaluations The change from baseline for most of the evaluations was not significantly different between the two groups (Supplementary Table 1 in Supplementary Material), except that after 3 months of administration there was a borderline significant difference at HbA1c between the two groups for subset individuals (−0.4 ± 0.5% for mcIRBP-19-BGE vs. 0.2 ± 0.8% for placebo, P = 0.051).

also in 11,409 other papers

borderline significanceP = 0.057so close (0.05 < p ≤ 0.1)

Results The oral administration of mcIRBP-19-BGE decreased with a borderline significance at fasting blood glucose (FBG; P = 0.057) and HbA1c ( P = 0.060).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.